Latest Insider Transactions at Icu Medical Inc (ICUI)
This section provides a real-time view of insider transactions for Icu Medical Inc (ICUI). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of ICU MEDICAL INC to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of ICU MEDICAL INC's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 08
2024
|
Ben Sousa Chief Information Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
240
-8.81%
|
$24,960
$104.52 P/Share
|
|
Mar 08
2024
|
Ben Sousa Chief Information Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
674
+19.84%
|
-
|
|
Mar 08
2024
|
Vivek Jain Chairman and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
5,953
-2.83%
|
$619,112
$104.52 P/Share
|
|
Mar 08
2024
|
Vivek Jain Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
10,856
+4.84%
|
-
|
|
Mar 08
2024
|
Brian Michael Bonnell Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,210
-10.1%
|
$541,840
$104.52 P/Share
|
|
Mar 08
2024
|
Brian Michael Bonnell Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,499
+15.16%
|
-
|
|
Mar 08
2024
|
George A Lopez Director |
SELL
Open market or private sale
|
Direct |
15,372
-4.59%
|
$1,614,060
$105.94 P/Share
|
|
Mar 08
2024
|
Virginia Ruth Sanzone VP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,246
-17.69%
|
$129,584
$104.52 P/Share
|
|
Mar 08
2024
|
Virginia Ruth Sanzone VP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,273
+24.4%
|
-
|
|
Mar 08
2024
|
Virginia Ruth Sanzone VP, General Counsel |
SELL
Open market or private sale
|
Direct |
3,300
-40.89%
|
$343,200
$104.57 P/Share
|
|
Mar 07
2024
|
Daniel Woolson VP, GM-Infusion Capital |
SELL
Payment of exercise price or tax liability
|
Direct |
2,990
-9.87%
|
$313,950
$105.39 P/Share
|
|
Mar 07
2024
|
Daniel Woolson VP, GM-Infusion Capital |
BUY
Exercise of conversion of derivative security
|
Direct |
6,758
+17.25%
|
-
|
|
Mar 07
2024
|
Christian B. Voigtlander Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,234
-52.89%
|
$864,570
$105.39 P/Share
|
|
Mar 07
2024
|
Christian B. Voigtlander Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,017
+49.09%
|
-
|
|
Mar 07
2024
|
Ben Sousa Chief Information Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,077
-29.87%
|
$113,085
$105.39 P/Share
|
|
Mar 07
2024
|
Ben Sousa Chief Information Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,003
+45.09%
|
-
|
|
Mar 07
2024
|
Vivek Jain Chairman and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
12,352
-5.87%
|
$1,296,960
$105.39 P/Share
|
|
Mar 07
2024
|
Vivek Jain Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,524
+9.29%
|
-
|
|
Mar 07
2024
|
Brian Michael Bonnell Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
8,234
-17.48%
|
$864,570
$105.39 P/Share
|
|
Mar 07
2024
|
Brian Michael Bonnell Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,017
+22.87%
|
-
|
|
Mar 07
2024
|
George A Lopez Director |
SELL
Open market or private sale
|
Direct |
18,954
-5.35%
|
$1,990,170
$105.77 P/Share
|
|
Mar 07
2024
|
Virginia Ruth Sanzone VP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
4,116
-20.31%
|
$432,180
$105.39 P/Share
|
|
Mar 07
2024
|
Virginia Ruth Sanzone VP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
7,509
+25.7%
|
-
|
|
Mar 04
2024
|
George A Lopez Director |
SELL
Open market or private sale
|
Direct |
7,051
-1.95%
|
$747,406
$106.79 P/Share
|
|
Mar 04
2024
|
Christian B. Voigtlander Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
13,603
-82.46%
|
$1,455,521
$107.56 P/Share
|
|
Feb 29
2024
|
Smiths Group International Holdings LTD |
SELL
Open market or private sale
|
Direct |
830,000
-33.2%
|
$87,980,000
$106.08 P/Share
|
|
Feb 29
2024
|
Smiths Group PLC |
SELL
Open market or private sale
|
Indirect |
830,000
-33.2%
|
$87,980,000
$106.08 P/Share
|
|
Feb 12
2024
|
Vivek Jain Chairman and CEO |
SELL
Payment of exercise price or tax liability
|
Indirect |
37,302
-29.6%
|
$3,879,408
$104.02 P/Share
|
|
Feb 12
2024
|
Vivek Jain Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Indirect |
66,000
+34.38%
|
$3,828,000
$58.79 P/Share
|
|
Feb 12
2024
|
Vivek Jain Chairman and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
82,725
-48.65%
|
$8,603,400
$104.02 P/Share
|
|
Feb 12
2024
|
Vivek Jain Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
146,366
+46.26%
|
$8,489,228
$58.79 P/Share
|
|
Dec 01
2023
|
Daniel Woolson VP, GM-Infusion Capital |
SELL
Open market or private sale
|
Direct |
1,729
-14.9%
|
$152,152
$88.03 P/Share
|
|
Sep 08
2023
|
Christian B. Voigtlander Chief Operating Officer |
SELL
Open market or private sale
|
Direct |
6,850
-17.47%
|
$883,650
$129.31 P/Share
|
|
Jul 12
2023
|
Vivek Jain Chairman and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-55.89%
|
$5,400,000
$180.02 P/Share
|
|
Jul 12
2023
|
Vivek Jain Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+35.85%
|
$1,740,000
$58.79 P/Share
|
|
Jun 14
2023
|
Vivek Jain Chairman and CEO |
SELL
Open market or private sale
|
Direct |
30,000
-10.49%
|
$5,700,000
$190.21 P/Share
|
|
Jun 14
2023
|
Vivek Jain Chairman and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
30,000
+9.09%
|
$1,740,000
$58.79 P/Share
|
|
Jun 07
2023
|
Elisha W Finney |
SELL
Open market or private sale
|
Direct |
194
-11.58%
|
$36,860
$190.41 P/Share
|
|
Jun 02
2023
|
Vivek Jain Chairman and CEO |
SELL
Bona fide gift
|
Direct |
85
-0.36%
|
-
|
|
May 17
2023
|
Kolleen T Kennedy |
BUY
Exercise of conversion of derivative security
|
Direct |
485
+44.13%
|
-
|
|
May 17
2023
|
David F Hoffmeister |
BUY
Exercise of conversion of derivative security
|
Direct |
485
+18.92%
|
-
|
|
May 17
2023
|
Elisha W Finney |
BUY
Exercise of conversion of derivative security
|
Direct |
485
+22.45%
|
-
|
|
May 17
2023
|
Donald Abbey |
BUY
Exercise of conversion of derivative security
|
Direct |
485
+18.92%
|
-
|
|
May 17
2023
|
David C. Greenberg Director |
BUY
Exercise of conversion of derivative security
|
Direct |
485
+10.6%
|
-
|
|
May 17
2023
|
Laurie Hernandez Director |
BUY
Exercise of conversion of derivative security
|
Direct |
485
+34.11%
|
-
|
|
Apr 11
2023
|
Virginia Ruth Sanzone VP, General Counsel |
SELL
Open market or private sale
|
Direct |
250
-5.07%
|
$43,750
$175.0 P/Share
|
|
Apr 05
2023
|
Virginia Ruth Sanzone VP, General Counsel |
SELL
Open market or private sale
|
Direct |
458
-8.5%
|
$77,860
$170.0 P/Share
|
|
Mar 08
2023
|
Virginia Ruth Sanzone VP, General Counsel |
SELL
Payment of exercise price or tax liability
|
Direct |
1,196
-18.17%
|
$186,576
$156.17 P/Share
|
|
Mar 08
2023
|
Virginia Ruth Sanzone VP, General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
2,272
+25.66%
|
-
|
|
Mar 08
2023
|
Daniel Woolson VP, GM-Infusion Capital |
SELL
Payment of exercise price or tax liability
|
Direct |
894
-7.15%
|
$139,464
$156.17 P/Share
|